ALC vs PEN vs OMCL Stock Comparison

Alcon, Penumbra and Omnicell Prices as of Oct 27, 2026 Peers: Industry group
ALC Alcon Inc
$69.42 +7.7% 1M -8.8% 1Y
Market cap
$34.41B
P/E
53.5x
Revenue (TTM)
$10.80B
Div. yield
–
Medical Devices Healthcare
1 win
PEN Penumbra Inc
$324.07 +1.6% 1M +30.7% 1Y
Market cap
$12.55B
P/E
78.2x
Revenue (TTM)
$1.50B
Div. yield
–
Medical Devices Healthcare
5 wins
OMCL Omnicell, Inc.
$36.76 +9.2% 1M +20.4% 1Y
Market cap
$1.64B
P/E
42.0x
Revenue (TTM)
$1.25B
Div. yield
–
Medical Devices Healthcare
3 wins

Head to Head

9 decided of 12

Penumbra leads on 5 of the 12 questions below (Penumbra 5, Omnicell 3, Alcon 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionALCPENOMCLLeader
Larger companyMarket capitalisation $34.41B $12.55B $1.64B ALC
Cheaper on earningsLower P/E, profitable companies only 53.5x 78.2x 42.0x OMCL
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.6x 72.3x 16.7x OMCL
Faster revenue growthRevenue growth, trailing twelve months +8.5% +17.6% +8.5% PEN
More profitableNet margin, trailing twelve months 6.0% 10.7% 3.1% PEN
Better return on capitalReturn on invested capital 3.6% — — –
Less leveragedLower net debt / EBITDA — — — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -8.8% +30.7% +20.4% PEN
Better 5-year returnAnnualised price return, 5 years -3.5%/yr +3.1%/yr -26.6%/yr PEN
Less volatileAnnualised volatility, 1 year 28.6% 26.4% 50.2% PEN
Higher overall scoreMean of the five percentile scores vs peers 68/100 74/100 76/100 OMCL

Percentile Scorecard

ALCPENOMCL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisALCPENOMCL
Valuation 79 #48 of 227 55 #103 of 227 97 #8 of 227
Growth 48 #114 of 219 93 #16 of 219 77 #52 of 219
Profitability 76 #50 of 206 86 #30 of 206 73 #56 of 206
Financial Health 60 #96 of 238 85 #36 of 238 40 #143 of 238
Shareholder Returns 74 #35 of 134 50 #68 of 134 91 #13 of 134
Overall 68 74 76
  • ALC ranked among 247 companies in Medical Devices and Diagnostics
  • PEN ranked among 247 companies in Medical Devices and Diagnostics
  • OMCL ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodALCPENOMCLSPY
1 month +7.7%+1.6%+9.2% -0.2%
3 months +0.4%+1.3%-14.6% +3.9%
6 months -7.9%-0.6%-19.2% +8.2%
Year to date -11.9%+4.2%-18.9% +12.9%
1 year -8.8%+30.7%+20.4% +12.3%
3 years -0.9%+68.1%+5.5% +87.4%
3 years, per year -0.3%+18.9%+1.8% +23.3%
5 years -16.1%+16.6%-78.7% +67.9%
5 years, per year -3.5%+3.1%-26.6% +10.9%
10 years —+401.7%+5.6% +261.1%
10 years, per year —+17.5%+0.5% +13.7%

Risk

MeasureALCPENOMCLSPY
Volatility, 1Y 28.6%26.4%50.2% 12.7%
Downside volatility, 1Y 28.8%17.7%49.5% 12.7%
Beta vs S&P 500, 1Y 0.380.060.98 1.00
Return / volatility, 1Y -0.311.160.41 0.97
Max drawdown, 5Y -38.4%-59.7%-86.6% -25.4%
From 52-week high -20.4%-9.8%-28.5% -1.2%
52-week high $87.18$359.40$51.39 $779.14
52-week low $62.02$225.54$29.57 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleALCPENOMCL
P/E now vs peer median 53.2xmedian 29.6x 79.4xmedian 29.6x 42.9xmedian 29.6x
P/S now vs peer median 3.1xmedian 2.9x 8.5xmedian 2.9x 1.3xmedian 2.9x
EV/EBITDA now vs peer median —median 17.4x 59.2xmedian 17.4x 10.1xmedian 17.4x
P/FCF now vs peer median 19.4xmedian 22.3x 59.1xmedian 22.3x 11.8xmedian 22.3x
P/B now vs peer median 1.6xmedian 2.3x 8.3xmedian 2.3x 1.3xmedian 2.3x
PEG now vs peer median 2.54median 1.04 1.04median 1.04 0.79median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsALCPENOMCL
Revenue $10.80B $1.50B $1.25B
Gross profit $6.17B $1.02B $558.13M
Operating income $948.00M $187.34M $57.96M
Net income $643.00M $160.59M $39.08M
Free cash flow $1.74B $215.91M $142.60M
R&D $1.43B $92.25M $88.39M
EPS (diluted) $1.30 $4.06 $0.84
Cash & equivalents $1.36B $205.27M $292.20M
Total debt $4.72B – –
Shares (diluted) 496.20M 39.57M 46.30M
Enterprise value $25.37B $10.26B $732.51M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricALCPENOMCL
P/E 53.2x 79.4x 42.9x
P/FCF 19.4x 59.1x 11.8x
P/Operating cash flow 14.6x 45.9x 9.2x
P/S 3.1x 8.5x 1.3x
P/B 1.6x 8.3x 1.3x
P/Tangible book 2.5x 8.4x 1.5x
EV/EBITDA – 59.2x 10.1x
EV/EBIT 38.4x 64.6x 23.9x
EV/Revenue 3.4x 8.0x 1.1x
EV/FCF 20.9x 56.1x 9.7x
EV/Operating cash flow 15.8x 43.6x 7.6x
PEG (3Y EPS CAGR) 2.54 1.04 0.79

Growth

14 metrics
MetricALCPENOMCL
Revenue growth (1Y) 8.5% 17.6% 8.5%
Revenue CAGR (3Y) 5.9% 17.1% 0.3%
Gross profit growth (1Y) 11.7% 20.0% 11.0%
Gross profit CAGR (3Y) 7.3% 19.9% 1.1%
Operating income growth (1Y) -34.3% 17.6% 274.9%
Operating income CAGR (3Y) 7.5% 73.0% 54.0%
Net income growth (1Y) -40.1% 8.7% 69.3%
Net income CAGR (3Y) 21.1% 76.7% 54.5%
EPS growth (1Y) -40.7% 7.8% 71.8%
EPS CAGR (3Y) 21.0% 76.1% 54.0%
Operating cash flow growth (1Y) 10.3% 37.9% 22.8%
Operating cash flow CAGR (3Y) 25.9% 146.0% -1.4%
Free cash flow growth (1Y) 7.5% 33.6% 33.5%
Free cash flow CAGR (3Y) 48.0% 650.9% 0.4%

Profitability

14 metrics
MetricALCPENOMCL
Gross margin 57.2% 67.8% 44.8%
EBITDA margin – 13.6% 11.0%
Operating margin 8.8% 12.4% 4.6%
Pretax margin 6.9% 13.5% 4.9%
Net margin 6.0% 10.7% 3.1%
FCF margin 16.1% 14.3% 11.4%
Operating cash flow margin 21.4% 18.5% 14.6%
Return on equity 2.9% 10.7% 3.1%
Return on assets 2.1% 8.3% 2.0%
Return on invested capital 3.6% – –
Return on capital employed 3.4% 11.0% 3.7%
Asset turnover 0.3x 0.8x 0.6x
Cash conversion (OCF / net income) 3.6x 1.7x 4.6x
Stock comp / revenue 1.6% 4.0% 3.6%

Financial Health

11 metrics
MetricALCPENOMCL
Debt / assets 15.2% – –
Debt / equity 0.2x – –
Net debt / EBITDA – – –
Debt / FCF 2.7x – –
Liabilities / assets 30.6% 22.5% 35.4%
Equity / assets 69.4% 77.5% 64.6%
Interest coverage 9.2x – –
Current ratio 2.1x 5.7x 1.6x
Quick ratio 1.3x 3.6x 1.2x
Cash ratio 0.7x 2.8x 0.7x
Altman Z-score – 19.22 2.61

Shareholder Returns

7 metrics
MetricALCPENOMCL
Dividend yield 0.4% – –
Net buyback yield 2.7% -0.2% 2.7%
Shareholder yield 3.1% -0.2% 2.7%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusALCPENOMCL
Forward P/E 21.6xFY2026 72.3xFY2026 16.7xFY2026
EPS, next fiscal year $3.22FY2026 $4.48FY2026 $2.20FY2026
EPS growth, next FY +7.7%FY2026 +16.7%FY2026 +35.8%FY2026
EPS growth, the year after +15.5% +42.6% -9.1%
Revenue, next fiscal year $10.50BFY2026 $1.63BFY2026 $1.16BFY2026
Revenue growth, next FY +4.3%FY2026 +16.3%FY2026 -1.8%FY2026
Revenue growth, the year after +8.1% +7.5% +7.1%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersALCPENOMCL
Held by institutions 48.8% 86.6% 100.0%
Institutions holding 629 451 307
Change in shares held, QoQ +5.3% +0.9% +2.6%
Institutions buying 225 195 176
Institutions selling 274 182 90
Buyers to sellers 0.82 1.07 1.96

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ALCPENOMCL
ALC 1.00 0.15 0.31
PEN 0.15 1.00 0.01
OMCL 0.31 0.01 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ALC, PEN and OMCL?

Alcon (ALC) is the largest by market capitalisation: Alcon (ALC) $34.41B, Penumbra (PEN) $12.55B, Omnicell (OMCL) $1.64B.

Which stock is cheaper, ALC, PEN and OMCL?

Omnicell (OMCL) trades on the lowest price-to-earnings ratio (Alcon (ALC) 53.5x, Penumbra (PEN) 78.2x, Omnicell (OMCL) 42.0x). On next year's consensus earnings, Omnicell (OMCL) is cheapest (Alcon (ALC) 21.6x, Penumbra (PEN) 72.3x, Omnicell (OMCL) 16.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Penumbra (PEN) grew revenue fastest over the trailing twelve months: Alcon (ALC) +8.5%, Penumbra (PEN) +17.6%, Omnicell (OMCL) +8.5%.

Which company is more profitable?

Penumbra (PEN) has the highest net margin (Alcon (ALC) 6.0%, Penumbra (PEN) 10.7%, Omnicell (OMCL) 3.1%).

Which stock has performed better?

Over the past year Penumbra (PEN) returned the most: Alcon (ALC) -8.8%, Penumbra (PEN) +30.7%, Omnicell (OMCL) +20.4%. Over five years, Penumbra (PEN) compounded fastest (Alcon (ALC) -3.5%/yr, Penumbra (PEN) +3.1%/yr, Omnicell (OMCL) -26.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Penumbra (PEN) has been the steadiest (Alcon (ALC) 28.6%, Penumbra (PEN) 26.4%, Omnicell (OMCL) 50.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ALC, PEN and OMCL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Penumbra (PEN) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.